X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Adstiladrin (nadofaragene firadenovec) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Adstiladrin (nadofaragene firadenovec-vncg) is a FDA-approved intravesical gene-therapy candidate, designed to deliver a copy of a gene encoding a human IFNα2b to the bladder urothelium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nadofaragene Firadenovec-vncg
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: Phase IVProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Under the collaboration, Ferring will get exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.
Lead Product(s): Microbiome-based Therapy
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: PharmaBiome
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 11, 2023
Details:
ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Under the agreement, Royalty Pharma is acquiring a 5.1 percentage royalty on net sales of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC, in the United States.
Lead Product(s): Nadofaragene Firadenovec-vncg
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $500.0 million Upfront Cash: $300.0 million
Deal Type: Agreement August 23, 2023
Details:
Adstiladrin (nadofaragene firadenovec-vncg) is the first and only FDA-approved non-replicating adenovirus vector-based therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors.
Lead Product(s): Nadofaragene Firadenovec-vncg
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
SI-6603 (condoliase), which contains Condoliase as its active pharmaceutical ingredient, is intended to treat lumbar disc herniation via a single, direct intradiscal injection.
Lead Product(s): Condoliase
Therapeutic Area: Musculoskeletal Product Name: SI-6603
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Rekovelle (follitropin delta) is a follicle-stimulating hormone made from recombinant human DNA that is used to promote follicular development in females with ovarian failure, reproduction and fertility.
Lead Product(s): Follitropin Delta
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Rekovelle
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Rebyota (live fecal microbiota-jslm) is the first and only microbiome-based treatment approved by the U.S. FDA to prevent recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older.
Lead Product(s): Live Fecal Microbiota-jslm
Therapeutic Area: Infections and Infectious Diseases Product Name: Rebyota
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Adstiladrin, an intravesical therapy administered every three months, targets the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.
Lead Product(s): Nadofaragene Firadenovec-vncg
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
